Donna Gustafson, a pancreatic cancer patient, became the first recipient of a personalized mRNA vaccine in a clinical trial exploring this novel immunotherapy. This groundbreaking approach aims to bolster the immune system, specifically T cells, to seek and destroy lingering cancer cells, thereby preventing recurrence. Early trial data, presented at the American Association for Cancer Research, indicates that patients who mount an immune response to the vaccine, like Gustafson, show significantly improved long-term survival rates. While cautioning that results are preliminary and derived from a small patient group, researchers are optimistic about the potential of these personalized mRNA vaccines to combat difficult-to-treat cancers like pancreatic cancer.
Read More
Revolution Medicines’ drug, daraxonrasib, has demonstrated “dramatic, practice-changing outcomes” in a pivotal Phase 3 trial for pancreatic cancer, nearly doubling typical survival length and significantly reducing the risk of death compared to chemotherapy. The daily pill met all primary and secondary endpoints, offering patients a median survival of 13.2 months, a substantial increase from the 6.7 months seen with chemotherapy. These “unprecedented” results target RAS mutations common in pancreatic cancer and are expected to usher in a new era of RAS-targeted treatments. The company plans to seek expedited FDA approval for this potentially transformative therapy.
Read More
Former Senator Ben Sasse revealed on Tuesday that he has been diagnosed with stage 4 pancreatic cancer and acknowledges the prognosis as terminal. Sasse, who previously served as a U.S. Senator for Nebraska and later as the president of the University of Florida, emphasized that he is ready to fight. His diagnosis highlights the aggressive nature of pancreatic cancer, which has a low survival rate due to the fact that it is often diagnosed in its advanced stages, with many patients facing advanced disease at the time of diagnosis.
Read More
John Q. Hosedrinker